# Eko Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eko-health

- Industry: Medical Devices & Equipment
- Headquarters: Oakland, US
- Website: www.ekohealth.com/
- Total disclosed funding: $141M
- Latest round: Series D (Jan 15, 2024)
- Investors on record: 22

## About

Founded in 2013 by co-founders Connor Landgraf, Tyler Crouch, and Jason Bellet and based in California, US, Eko Health, Inc. is a developer and marketer of cardiac screening devices used to monitor and analyze a patient's heart sound and electrocardiogram data for the diagnosis of heart conditions.  In June 2024, Eko Devices, Inc. raised USD 27.43 million in Series D funding from investors Double Point Ventures, EDB, LG Technology Ventures, ARTIS Ventures, Highland Capital Partners, NTT Venture Capital, and Questa Capital Management. The Series D funding values Eko Devices, Inc. at USD 241.19 million post-money.
 
Eko's core product is a line of digital stethoscopes. These stethoscopes amplify and filter heart and lung sounds, allowing for more accurate diagnoses.  Eko Health offers a range of digital stethoscopes and related software. The flagship product combines traditional stethoscope features with advanced digital enhancements, including TrueSound audio, 3-lead ECG, and a full-colour display. The Eko Core Digital Stethoscope combines stethoscope functionality with digital amplification and noise cancellation. The 3M Littmann CORE Digital Stethoscope integrates Eko's digital technology with Littmann's cardiology-grade stethoscopes. The Eko Core Digital Attachment allows healthcare professionals to convert their existing analogue stethoscopes into digital devices. These products are designed to improve auscultation quality and facilitate the detection of heart and lung conditions. Additionally, the company offers an AI-powered software platform that detects structural murmurs and low ejection fraction, aiding in the early identification of heart disease.
 
The company generates revenue through its monthly subscription plan, which costs USD 9.99 per month per user (an annual subscription billed upfront for USD 119.99, or USD 12.99 if billed monthly) for EKO + Membership. Additionally, the firm also generates revenue by selling the products through its website, which ranges from USD 259 to USD 399.
 
 
The company will use the funding to increase access to the company's early disease detection platform in the United States and worldwide.

## Funding rounds

- Series D, Jan 15, 2024, $27M — Highland Capital Partners, SG Growth Capital, ARTIS Ventures, Questa Capital, LG Technology Ventures, NTT Venture Capital, Double Point Ventures
- Series C, Mar 22, 2022, $30M — PROOF.VC, Morningside
- Series C, Oct 14, 2020, $58M — Highland Capital Partners, ARTIS Ventures, 3M Ventures, Questa Capital, DigiTx Partners, NTT Venture Capital
- Series B, Sep 25, 2019, $20M — Mayo Clinic Ventures, ARTIS Ventures, Seraph Group, 3M Ventures, DigiTx Partners, NTT Venture Capital, XTX Ventures
- Series A, Feb 27, 2018, $3.1M — Mayo Clinic Ventures, ARTIS Ventures, DreamIt Ventures, Sutter Health, Strategic Partners, Founder.org, DigiTx Partners, 1812 Ventures
- Seed, Jan 14, 2015, $2.8M — Founder.org, SGH Capital, Stanford-StartX Fund, The House Fund

## Investors

- Founder.org — Seed, Series A
- SGH Capital (https://capitalatlas.ai/funds/sgh-capital) — Seed
- Stanford-StartX Fund — Seed
- The House Fund (https://capitalatlas.ai/funds/the-house-fund) — Seed
- Mayo Clinic Ventures (https://capitalatlas.ai/funds/mayo-clinic-ventures) — Series A, Series B
- ARTIS Ventures (https://capitalatlas.ai/funds/artis-ventures) — Series A, Series B, Series C, Series D
- DreamIt Ventures (https://capitalatlas.ai/funds/dreamit-ventures) — Series A
- Sutter Health — Series A
- Strategic Partners — Series A
- DigiTx Partners (https://capitalatlas.ai/funds/digitx-partners) — Series A, Series B, Series C
- 1812 Ventures — Series A
- Seraph Group (https://capitalatlas.ai/funds/seraph-group) — Series B
- 3M Ventures (https://capitalatlas.ai/funds/3m-ventures) — Series B, Series C
- NTT Venture Capital (https://capitalatlas.ai/funds/ntt-venture-capital) — Series B, Series C, Series D
- XTX Ventures (https://capitalatlas.ai/funds/xtx-ventures) — Series B
- Highland Capital Partners (https://capitalatlas.ai/funds/highland-capital-partners) — Series C, Series D
- Questa Capital (https://capitalatlas.ai/funds/questa-capital) — Series C, Series D
- PROOF.VC (https://capitalatlas.ai/funds/proof-vc) — Series C
- Morningside (https://capitalatlas.ai/funds/morningside) — Series C
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series D
- LG Technology Ventures (https://capitalatlas.ai/funds/lg-technology-ventures) — Series D
- Double Point Ventures (https://capitalatlas.ai/funds/double-point-ventures) — Series D